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Pelizaeus-Merzbacher-like Disease
Caused by AIMP1/p43 Homozygous Mutation
Miora Feinstein,1 Barak Markus,1 Iris Noyman,2 Hannah Shalev,2 Hagit Flusser,2 Ilan Shelef,3
Keren Liani-Leibson,1 Zamir Shorer,2 Idan Cohen,1 Shareef Khateeb,1 Sara Sivan,1 and Ohad S. Birk1,4,*
Pelizaeus-Merzbacher disease is an X-linked hypomyelinating leukodystrophy caused by PLP1mutations. A similar autosomal-recessive
phenotype, Pelizaeus-Merzbacher-like disease (PMLD), has been shown to be caused by homozygous mutations in GJC2 or HSPD1. We
report a consanguineous Israeli Bedouin kindredwith clinical and radiological findings compatible with PMLD inwhich linkage to PLP1,
GJC2, and HSPD1 was excluded. Through genome-wide homozygosity mapping and mutation analysis, we demonstrated in all affected
individuals a homozygous frameshift mutation that fully abrogates the main active domain of AIMP1, encoding ARS-interacting multi-
functional protein 1. The mutation fully segregates with the disease-associated phenotype and was not found in 250 Bedouin controls.
Our findings are in line with the previously demonstrated inability of mutant mice lacking the AIMP1/p43 ortholog to maintain axon
integrity in the central and peripheral neural system.The prototype of early-onset hypomyelinating leukodys-
trophies is X-linked Pelizaeus-Merzbacher disease (PMD
[MIM 312080]), caused by mutations in PLP1 (MIM
300401) encoding proteolipid protein lipophilin, which
is the predominant myelin protein present in the central
nervous system (CNS).1 Pelizaeus-Merzbacher-like disease
(PMLD [MIM 608804, 612233]) is clinically and neurora-
diologically similar to classical PMD but is not associated
with PLP1 mutations.2 Autosomal-recessive PMLD was
shown to be caused by recessive heterogeneous mutations
in GJC2 (MIM 608803) encoding one of the Gap-junction-
protein family of homologous connexins. GJC2 is
expressed specifically in oligodendrocytes, and its expres-
sion is regulated in parallel with other myelin genes.3,4
Other cases of recessive PMLD were demonstrated to be
due to mutations in HSPD1 (MIM 118190). HSPD1 is
a member of the heat shock protein (HSP) family, proteins
that are highly conserved throughout evolution and that
play a crucial role in cell maintenance and survival. The
protein encoded by HSPD1, also known as mitochondrial
Hsp60 chaperonin, is a major component of the protein-
folding system inside the mitochondrial matrix. Hsp60,
together with its cochaperonin Hsp10, produces large
and efficient protein-editing machinery that facilitates
proper folding and assembly of mitochondrial-imported
proteins and corrects misfolded polypeptides generated
under mitochondrial oxidative stress.2 In the past few
years, further cases of PMLD have been demonstrated in
which no GJC2 or HSPD1mutations were found, implying
the presence of yet-undiscovered PMLD loci and/or genes.2
Six individuals of three related families of consanguineous
Israeli Bedouin kindred, as well as a single individual of
another very remotely related consanguineous family of
the same tribe, presented with apparently autosomal-reces-1The Morris Kahn Laboratory of Human Genetics at the National Institute of B
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820 The American Journal of Human Genetics 87, 820–828, DecembsivePMLD(Figure1).Themedical recordsof all sevenaffected
individualswere reviewed, and four of the survivingfive indi-
viduals underwent careful clinical evaluation by a pediatric
neurologist and a clinical geneticist, followed by thorough
biochemical laboratory testing and MRI. The study was
approved by the Institutional Review Board of Soroka
Medical Center, and informed consent was obtained from
all participants or their legal guardians. In all four affected
individuals that were studied in depth (with similar findings
in the records of the three other patients), the disease pheno-
type was of severe rapid neurological deterioration progress-
ingover the firstmonths of life.As seen inTable 1, all affected
individuals had severe failure to thrive (weight 3.5–4.5 stan-
dard deviation [SD] below average), with a concordant head
circumference 2.5–4 SD below average. All had severe global
developmental delay/mental retardationwith lack of speech,
as well as axial hypotonia. Progressive spastic paraparesis
appeared within the first year, with wasting of lower limbs
and positive pyramidal signs. Progressive joint contractures
and kyphoscoliosis were evident as early as 2–3 years of
age. Fast horizontal or rotary nystagmus, evident at age
2–3 months, was the presenting sign in most patients. All
had coarse faces, most had slow pupillary reflexes, and two
of the patients had seizures. Abnormal EEG patterns were
noted: patient III-25, tested at age 9 months, had slow back-
ground with numerous slow generalized and bilateral spike
activity.Patient IV-3, testedat2and4.5years,hadgeneralized
epileptiformactivity. Patients II-1 (kindred2), IV-3, and III-25
(Figure 1) underwent intensive laboratory work: complete
blood count, routine blood chemistry, creatine-phosphoki-
nase, cholesterol and triglycerids, ammonia, thyroid func-
tion tests, blood pH, lactate, pyruvate, blood amino acids,
carnitine, acylcarnitine, very long chain fatty acids, and bio-
tinidase were normal in all patients, as were urine tests foriotechnology in the Negev, Beer Sheva 84101, Israel; 2Division of Pediatrics,
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Figure 1. Pedigree of the Affected Israeli Bedouin Kindred
(A and B) The pedigree is compatible with autosomal-recessive heredity. (A) and (B) are branches of a single extended tribe, remotely
related (not first or second degree).mucopolysaccharides and oligosaccharides and cerebro-
spinal fluid tests for glucose, protein, and cells. Vanillylman-
delic acid was in normal range for patient II-1. Enzymatic
assays ruled out metachromatic leukodystrophy (MIM
250100) and Krabbe disease (MIM 245200) for patients
III-25 and II-1, as well as Gangliosidosis type 1 and 2 (MIM
230500, 230600) and neuronal ceroid lipofuscinosis types 1
and 2 (MIM 256730, 204500) for patient II-1. Rectal biopsy
for patient III-25 demonstrated no evidence of a storage
disease.
MRI findings were very similar in all affected individuals,
showing arrest of myelination. The T2-weighted images
showed high signal of hypomyelination starting at
a normal stage (Figure 2A), as well as high signal on flair
(Figure 2B). These findings were seen as low signal on T1-
weighted images (Figure 2D). On diffusion-weighted
images, exponential apparent diffusion coefficient (eADC)
showed low signal (Figure 2E), representing increasedThe Americandiffusivity secondary to hypomyelinated brain tissue.
Magnetic resonance spectroscopy demonstrated relative
decrease of N-acetylaspartate within the white matter,
likely because of axonal degeneration (Figure 2C). General-
ized brain atrophy, especially of the corpus callosum
(Figure 2F), was noted.
DNA samples of the five surviving patients and 14 of
their first-degree relatives were available for molecular
analyses. With a clinical diagnosis of PMLD, and assuming
a founder effect, we used microsatellite markers (as previ-
ously described)5 to test the affected individuals for homo-
zygosity at the loci of GJC2 and HSPD1, whose mutations
are known to cause PMLD. In short, genomic DNA was
extracted from peripheral lymphocytes, and microsatellite
markers were derived from Marshfield maps.6 Intronic
primer pairs were designed with the Primer3 (version
0.4.0) software, based on DNA sequences obtained from
UCSC Genome Browser (sequences available on request).Journal of Human Genetics 87, 820–828, December 10, 2010 821
Table 1. Clinical Signs and Symptoms
Clinical Sign/Symptom Patient III-16 Patient III-25 Patient IV-3 Patient II-1, Kindred 2 Patient III-6 Patient III-5 Patient III-26
Present age 19 yrs. 15 yrs. 5 yrs. 16 mos. 26 yrs. Died 13 yrs. Died 24 yrs.
Weight (percentile) 4.5 SD 4.5 SD 3.5 SD 3.5 SD FTT FTT FTT
Head circumference
(percentile)
4 SD 4 SD 4 SD 2.5 SD ND ND ND
Global developmental
delay/mental retardation
Severe Severe Severe Severe Severe Severe Severe
Seizures  þ þ   ND ND
Mild dysmorphism þ þ þ þ þ þ þ
Sight Impaired Impaired Impaired Impaired Impaired Impaired Impaired
Speech       
Nystagmus: age of
onset (mos.)
2 1.5 3 2 2–3 2–3 2–3
Exotropia   þ þ ND ND ND
Slow pupillary reflex þ þ þ - ND ND ND
Pale fundi þ þ - - ND ND ND
Axial hypotonia þ þ þ þ þ þ þ
Limb spasticity/spastic
paraparesis
þ þ þ þ þ þ þ
Pyramidal signs þ þ þ þ ND ND ND
Wasting of lower limbs þ þ þ  þ þ þ
Kyphoscoliosis þ þ þ  þ þ þ
Joint contractures þ þ þ  þ þ þ
The following abbreviations are used: FTT, failure to thrive, no precise measurements available; ND, no data available.Polymerase chain reaction (PCR) products were separated
on polyacrylamide gel with silver staining for detection
as previously described.6 Affected individuals did not share
homozygosity at any of the two loci (data not shown).
Next, we did genome-wide linkage analysis with Affyme-
trix GeneChip HumanMapping 500K Set Nsp microarrays,
testing five affected individuals (subjects III-6, III-16, III-25,
and IV-3of kindred1andsubject II-1of kindred2) andseven
of their first-degree relatives, according to the Affymetrix
GeneChipMappingAssayprotocol aspreviouslydescribed.6
Homozygosity by descent analysis was carried out with an
in-house-generated tool for homozygosity mapping (B.M.
and O.S.B., unpublished data). The analysis identified
a 9.52 Mb segment of homozygosity on chromosome
4q23-q25 that was common to all five patients. Few addi-
tional significantly smaller regions of shared homozygosity
shorter than 1 Mb were spotted. However, because none of
these were contained within larger stretches of individual
homozygosity, we first analyzed the 4q23-q25 locus. Fine
mapping of this locus was performed on samples of the
five samples of affected individuals included in the study
and their close relatives by genotyping with additional mi-
crosatellite markers derived from Marshfield maps or with
novel markers designed based on Tandem Repeats Finder822 The American Journal of Human Genetics 87, 820–828, Decemb(TRF) program and the UCSC Human Genome Database.
Analysis with polymorphic markers chr4:98663671-
98663717, D4S1647, and D4S1564 narrowed down the
4q23-q25 region to 8.94 Mb spanning 867 consecutive
SNPs betweenmarkers rs10026181and rs203202 at physical
positions 98814118 and 108329618, respectively. Genotyp-
ing with eight additional microsatellite markers within the
homozygosity interval in five affected children and their
close relatives (Figure 3) further substantiated the identifica-
tion of the chromosome 4q23-q25 interval as the disease-
associated locus. Multipoint LOD score calculation with
SUPERLINK7 was done for markers D4S1647, D4S2634,
D4S421, D4S1591, chr4:103271298-103271353,
chr4:104134017-104134065, D4S2913, chr4:106364749-
106364794, and chr4:107336226-107336269 on 4q24
(kindred 1, Figure 1). The calculations were done assuming
an autosomal-recessive mode of inheritance with pene-
trance of 0.99, a disease mutant gene frequency of 0.01,
and a uniform distribution of allele frequencies. The
maximum multipoint LOD score calculated for kindred 1
was 4.25. All affected individuals in both kindreds 1 and 2
shared a commonhomozygous haplotype betweenmarkers
D4S2634 and chr4:107336226-107336269, supporting
a common ancestral origin for this locus.er 10, 2010
Figure 2. MRI of Two Affected Individuals
(A–C) Girl age 5 years with severe form of PMLD. The images
demonstrate arrested myelination and reduced N-acetylaspartate.
The T2-weighted images showed high signal of hypomyelination
starting at a normal stage (A), as well as high signal on flair (B).
The AmericanWe next proceeded to prioritize and sequence candidate
genes within the identified locus. The clinical presentation
of the patients of both kindred was determined to be
similar to PMLD. Thus, to obtain a prioritized list of the
39 candidate genes within the locus, we used our
Syndrome to Gene (S2G) software,8 inserting GJC2 (whose
mutations are known to cause PMLD) as a reference gene.
Because we find sequencing of lymphoblastoid cDNAmore
efficient than sequencing genomic DNA (when possible),
we did Epstein Barr virus (EBV) transformation of lympho-
cytes of affected individuals as previously described.9 RNA
was extracted from cultured cells of EBV-transformed lym-
phoblastoid cell lines with the RNeasy Mini Kit (QIAGEN),
and cDNAwas reverse transcribed by the Verso RT-PCR kits
(TAMAR) according to the manufacturer’s protocol.10
Primer pairs for PCR amplification from cDNA and/or
exons of genomic DNA (including flanking intron
sequences) of the 39 genes in the putative 4q24 locus
were designed based on the known mRNA and genomic
sequences with Primer3. Primer sequences and PCR condi-
tions are available upon request. PCR products were
directly sequenced with ABI PRISM 3730 DNA Analyzer
according to the protocols of themanufacturer (Applied Bi-
osystems). Sequence variations (Table 2) were confirmed
by bidirectional sequencing. Sequencing of the entire
coding region and intron-exon borders of the top 15% of
the genes on the prioritized list identified a single frame-
shift mutation common to all affected individuals:
a c.292_293delCA (p.Gln98ValfsX30) mutation in exon 4
of AIMP1/p43, position 292–293 in the UCSC Consensus
Coding Sequence, variant NM_001142415.1 (Figure 4).
The mutation is predicted to truncate the major conserved
functional domains of AIMP1 (Figure 4). Testing for the
AIMP1 mutation in the entire family and controls was
done via restriction analysis, based on the fact that the
mutation abrogates an HpyCH4III restriction site. Because
there is another HpyCH4III recognition site only 17 bp
apart (that is common to both wild-type and mutated
sequences, based on New England Biolabs NEBcutter),
PCR primer pairs were designed in which the reverse
primer included part of that second HpyCH4III site, intro-
ducing a single nucleotide change (A314T) that eliminates
this second HpyCH4III restriction site. PCR amplification
of genomic DNA with this primer set gave a 198 bp frag-
ment, generating HpyCH4III (TaaI-Fermentas) differential
cleavage products of the mutant (uncut, 198 bp) versus
wild-type alleles (158 bp and 40 bp). Fragments wereMagnetic resonance spectroscopy demonstrated relative decrease
of N-acetylaspartate within the white matter, likely because of
axonal degeneration (C).
(D–F) Girl age 14 months with severe form of PMLD. The images
demonstrate incomplete myelination and corpus callosum
atrophy. These findings were seen as low signal on T1-weighted
images (D). On diffusion-weighted images, eADC showed low
signal (E) representing increased diffusivity secondary to hypo-
myelinated brain tissue. Generalized brain atrophy, especially of
the corpus callosum, was noted (F).
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Figure 3. Fine Mapping of the 4q24
Locus in Kindred 1 and Kindred 2
(A) Disease-associated haplotype shown in
boxes. Markers D4S2634 and
chr4:107336226-107336269 define the
minimal homozygosity locus associated
with the disease. Blank spaces indicate
nongenotyped markers.
(B) Schematic presentation of the defined
locus and the genes it contains (UCSC).
Markers within the homozygosity locus
are boxed.separated by electrophoresis on 3% agarose gel. PCR
amplification primers were F-50-AGAGTTCCCATTTGTGG
TTCA-30 and R-30-TTCTTTGGTACCAGAAGATTCGG-50.
Using this restriction analysis, we showed complete
segregation (and thus full penetrance) of the mutation
with the disease-associated phenotype in all investigated
family members, heterozygosity in all obligatory carrier
parents, and no homozygosity in nonaffected individuals.
The mutation was not present in 500 chromosomes of
healthy ethnically matched control samples. Sequencing
the entire coding region and intron-exon borders of 13
other genes and partial sequences of 12 additional genes
within the 4q23-q25 locus (some of which were not pre-
dicted by S2G) identified no further mutations in those
individuals (data not shown).824 The American Journal of Human Genetics 87, 820–828, December 10, 2010We have thus showed through
homozygosity mapping,11,12 followed
by mutation analysis of candidate
genes within the 4q24 locus, a homo-
zygous frameshift mutation in AIMP1/
p43 as the cause of an autosomal-
recessive hypomyelinating leukodys-
trophy with the characteristics of
PMLD. Prioritizing of candidate genes
within the defined locus was done
with S2G.8 The software selects a prior-
itized list of candidate genes for any
syndrome, based on their known
molecular interactions with genes
associated with phenotypically
similar syndromes. It is of interest to
note that AIMP1 was in the top 15%
of the S2G prioritized list of 39 genes
within the 4q23-q25 locus, demon-
strating the effectiveness of our S2G
software in the identification of
disease genes.
AIMP1 has three splice variants
(RefSeq NM_001142415.1, NM_00114
2416.1, NM_004757.3), two of which
encode the same 312 aa protein
product. The deletion leads to a frame-
shift mutation, p.Gln98ValfsX30, dis-rupting the original protein sequence after 97 aa, causing
the early appearance of a stop codon at position 127 in two
splice variants. The third splice variant (NM_001142416.1)
contains a c.364_365delCA mutation that leads to
a mutant protein sequence (p.Gln122ValfsX30). The
deleted part in the mutant protein contains the most
important AIMP1/p43 predicted domains (derived from
SMART13) that are highly conserved across AIMP1/p43
homologs from seven different nonhuman species
(Figure 3E). The truncated protein lacks the tRNA-binding
domain (aa 151–252), a domain needed for interaction
with HSP90B1 (aa 54–195), and a segment required for
induction of inflammation (aa 147–312), as well as regions
that control angiogenesis by a biphasic mechanism,
manipulating tube formation and endothelial cell death
Table 2. Gene Variants Found in Sequencing of DNA Sample of
Affected Individual
Gene SNP
MANBA rs227368
DDIT4L rs58706659, rs56763427
CENPE rs61751592
NPNT rs4340795(aa 114–192 and aa 101–114), respectively. All domain loca-
tions refer to variants NP_001135887 and NP_004748
(Figures 3D and 3E).14
AIMP1 (initially termed P43) is known to undergo
cleavage by caspase 7 in response to apoptosis to produceThe Americanendothelial monocyte-activating polypeptide II (EMAP-
II), which is involved in the control of angiogenesis, inflam-
mation, and wound healing.14 The release of this cytokine
renders the tumor-associated vasculature sensitive to tumor
necrosis factor.15 The part of the AIMP1 protein that is
essential for these functions (that is missing in themutated
protein, Figure 4) is extremely conserved throughout evolu-
tion. Interestingly, the affected individuals did not present
with any clinically significant immunedeficiency. It is plau-
sible that the failure of thepatients to thrivemight bedue in
part to disturbances in angiogenesis. However, further
studies are required to discern possible subtle effects of the
AIMP1 mutation on angiogenesis and inflammation in
the affected individuals of this kindred.
The neurological phenotype seen in the patients is not
surprising. There is ample evidence of a major role ofFigure 4. The c.292_293delCA Mutation
in Exon 4 of AIMP1
(A–C) Sequence analysis is shown for an
unaffected individual (A), an obligatory
carrier (B), and an affected individual (C).
(D) SMART display of human AIMP1
domains along the wild-type sequence
versus the mutant protein. The aberrant
region in the mutant protein includes the
tRNA-binding domain, a sequence needed
for interaction withHSP90B1, and a region
required for endothelial cell death and
migration.13 The protein sequence is
altered after 97 aa, and a stop codon trun-
cates the protein after 127 aa.
(E) Conservation of AIMP1 domains
throughout evolution. Deleted area is
boxed.
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AIMP1 in neurons: the AIMP1/p43 mouse ortholog has
been shown to be expressed in neurons of the CNS and
the spinal cord in mice and to be associated directly with
NF-L (light chain of the neurofilaments), modulating their
phosphorylation and assembly in the neuronal network.
NF-L is the pivotal subunit of NFs, the major intermediate
filament (IF) of neurons and axons, and it plays a crucial
role in the maintenance of the neural cytoskeleton in the
CNS.16–20 Depletion of the AIMP1/p43 protein causes hy-
perphosphorylation of NF proteins and NF network disas-
sembly in primary cultured neurons and motor axons,
resulting in phenotypes similar to those observed in mice
lacking the mouse ortholog of NEFL (MIM 162280, encod-
ing NF-L). The hyperphosphorylation of NFs in mutant
mice lacking the functional AIMP1/p43 mouse ortholog
could result from activation of certain kinases that are
otherwise suppressed by AIMP1/p43 under physiological
conditions.21–24 Thus, AIMP1/P43 functions in a funda-
mental role of regulating NF-L and maintains CNS-cyto-
skeleton integrity. Because of its interaction with NF-L,
and because of NF-L’s association to Charcot-Marie-Tooth
(CMT) neuropathies, AIMP1 has also been suggested to
be a potential molecular linker between components of
the protein biosynthesis machinery (ARSs) and NFs in
CMT neuropathy, on the basis of similarity between clin-
ical features of the disease and those of AIMP1 null
mice.15,20 Because AIMP1 is classified as a fundamental
regulator of NF-L and thus a regulator of axon develop-
ment and maintenance,20 its molecular interactions with
NF-L are likely associated with the disease mechanism in
the kindred studied.
Mutations in NEFL cause autosomal-dominant neuropa-
thies that are classified either as axonal CMT type 2 (CMT2
[MIM 607648]) or demyelinating CMT type 1 (CMT1 [MIM
607734]) diseases. CMT patients have motor and sensory
neuropathies characterized by progressive muscular
atrophy and sensory loss in the distal limbs.17 CMT1
usually results from myelin alteration, and histological
examination of CMT1 neurons often reveals extensive
segmental demyelination and remyelination.18 CMT1
patients studied over the last decade presented diverse
phenotypes, including mental retardation, pyramidal
signs, and cerebellar atrophy.19 It has been suggested that
mutant NF-L subunits cause neurological disease through
altering the formation andmaintenance of the cytoskeletal
network,16 and studies have shown the connection of NF-L
to neurodegenerative diseases.
AIMP1 also functions as a noncatalytic component of
the multisynthetase complex. This complex is comprised
of a bifunctional glutamyl-prolyl-tRNA synthetase, the
monospecific isoleucyl, leucyl, glutaminyl, methionyl, ly-
syl, arginyl, and aspartyl tRNA synthetases, and three
auxiliary proteins, EEF1E1/p18, AIMP2/p38, and AIMP1/
p43, together catalyzing the ligation of amino acids to
their cognate tRNAs.25 Although tRNA formation and pro-
cessing are obviously essential in all tissues of the human
body, disturbances in such processes have been shown to826 The American Journal of Human Genetics 87, 820–828, Decemblead to human phenotypes that affect mostly the nervous
system. Pontocerebellar hypoplasia (PCH) is a heteroge-
neous group of disorders characterized by an abnormally
small cerebellum and brainstem. PCH type 2, characterized
by progressive microcephaly combined with extrapyra-
midal dyskinesia and chorea, epilepsy, and normal spinal
cord findings, is caused by mutations in genes involved
in tRNA processing: TSEN54, TSEN2, and TSEN34, which
are subunits of the tRNA splicing endonuclease complex.26
Furthermore, we have recently demonstrated that
a homozygous mutation in SepSecS (which normally cata-
lyzes the conversion of Sep-tRNA to Sec-tRNA) abrogates
the formation of the 21st amino acid selenocyetsine (the
only genetically encoded amino acid in humans whose
biosynthesis occurs on its cognate tRNA), leading to
a neurodegenerative phenotype of progressive cerebrocere-
bellar atrophy presenting with nondysmorphic profound
mental retardation, progressive microcephaly, and severe
spasticity with myoclonic or generalized tonic-clonic
seizures.27 Thus, it is not surprising that a mutation in
a molecule essential for tRNA formation or processing
leads to a neurospecific human phenotype.
Further support of the AIMP1mutation being the under-
lying cause of the PMLD phenotype comes from the
phenotype of mutant mice lacking the functional
AIMP1/P43 ortholog:20 mice lacking the AIMP1/p43
ortholog in their central nervous system displayed weight
loss and spontaneous spastic tremors, could not extend
their hind limbs when suspended by the tail, and exhibited
slower gaits and decreased motor activity. Histological
studies showed widespread muscle atrophy with
pronounced atrophy of the large gastrocnemius muscle
of the hind limb (much like that shown in the patients),
including the reduction of muscle fiber density, muscle
atrophy, fibrosis, and clustering of muscle fibers.20
In conclusion, we have identified a homozygous
deletion mutation in AIMP1/p43 as the cause of a severe
neurodegenerative disorder whose phenotype is commen-
surate with the diagnosis of PMLD with coarse face as
a unique feature. Our findings allow carrier testing and
early prenatal diagnosis in a large consanguineous popula-
tion in southern Israel and hopefully in other PMLD fami-
lies worldwide. The molecular mechanisms underlying the
phenotype are likely associated with the role of AIMP1 in
NF-L phosphorylation, affecting maintenance of the
neural cytoskeleton in the CNS. The phenotype might
arise in part also from abrogation of the function of
AIMP1 in a complex catalyzing the ligation of amino acids
to their cognate tRNAs. Molecular cascades possibly tying
together AIMP1 with PLP1, GJC2, or HSPD1, whose muta-
tions cause similar phenotypes, are yet to be elucidated.Acknowledgments
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